Coagulo Medical Technologies

Coagulo is at the forefront of personalized coagulation management, offering a groundbreaking precision medicine platform that identifies abnormalities across the entire clotting cascade. The company leverages patent-pending coagulation assays, cutting-edge microfluidic technology, and proprietary data analytics to provide clinically valuable information that no other technology can deliver. Coagulo's innovative point-of-care testing platform is the first of its kind, enabling accessible and personalized diagnosis and management of all coagulation-related diseases. This technology is particularly crucial for the 10 million people in the U.S. on anticoagulants, which are the leading cause of drug-related adverse events and hospitalizations. The platform aims to replace outdated coagulation tests, which are over 50 years old and offer limited insights, with a more precise and comprehensive approach. Coagulo serves healthcare providers, researchers, and patients, operating in the medical diagnostics market. The business model primarily involves the development and investigational use of in vitro diagnostic products, which are not yet available for commercial sale or clinical diagnostic use. Revenue is generated through partnerships, research collaborations, and potential future sales of its diagnostic platforms once they receive regulatory approval.

Keywords: precision medicine, coagulation management, diagnostics, microfluidic technology, data analytics, point-of-care testing, anticoagulants, personalized care, healthcare outcomes, clinical treatments.